CYP3A5

Preemptive Pharmacogenetics in Renal Transplantation: A Real-World Assessment of Pharmacogenetic Actionability

Renal transplantation — preemptive pharmacogenetics

Integrating pharmacogenetic and clinical factors to predict the C0/D/W-based tacrolimus phenotype in kidney transplantation

Tacrolimus — pharmacogenetic prediction of pharmacokinetic phenotype (C0/D/W) in kidney transplantation by integrating CYP3A4/CYP3A5 variants and clinical factors

Effects of CYP3A4, CYP3A5, and ABCB1 genetic variants on tacrolimus metabolism during the early period after kidney transplantation

Kidney transplantation and tacrolimus exposure

A Review of Population Pharmacokinetic Models and Dosing Algorithms Assessing the Influence of CYP3A5 Genotype and Other Clinical Covariates on Tacrolimus Pharmacokinetics.

Organ transplantation — tacrolimus dosing

Population pharmacokinetics of tacrolimus and CYP3A5-driven variability: implications for model-informed dose individualization in pediatric renal transplant recipients.

Tacrolimus PK variability in pediatric renal transplantation

Toward individualized precision dosing of perampanel: Integrating therapeutic drug monitoring, drug-drug interactions, and pharmacogenetics.

Drug-resistant epilepsy — individualised perampanel dosing

Association of a CCB-Related Pharmacogenomics-Guided Strategy with Blood Pressure Outcomes and Short-Term Safety in Chinese Patients with Hypertension: A Secondary Exploratory Analysis of Two Randomized Cohorts.

Hypertension treated with calcium channel blockers